首页 | 本学科首页   官方微博 | 高级检索  
检索        

托伐普坦治疗慢性肺源性心脏病心力衰竭疗效研究
引用本文:熊汉忠,朱立欢,魏宇淼.托伐普坦治疗慢性肺源性心脏病心力衰竭疗效研究[J].中国药业,2021(7):40-43.
作者姓名:熊汉忠  朱立欢  魏宇淼
作者单位:湖北省鄂州市中心医院;湖北省武汉协和医院
基金项目:国家自然科学基金[81873491]
摘    要:目的 探讨托伐普坦治疗慢性肺源性心脏病(简称肺心病)心力衰竭的疗效.方法 选取湖北省鄂州市中心医院2016年3月至2019年2月收治的慢性肺心病心力衰竭患者104例,按随机数字表法分为研究组和对照组,各52例.对照组患者采用托拉塞米治疗,研究组患者采用托伐普坦治疗.两组均治疗1周.结果 研究组总有效率为98.08%,明...

关 键 词:慢性肺源性心脏病  心力衰竭  托伐普坦  托拉塞米  疗效

Efficacy of Tolvaptan in the Treatment of Chronic Pulmonary Heart Disease with Heart Failure
XIONG Hanzhong,ZHU Lihuan,WEI Yumiao.Efficacy of Tolvaptan in the Treatment of Chronic Pulmonary Heart Disease with Heart Failure[J].China Pharmaceuticals,2021(7):40-43.
Authors:XIONG Hanzhong  ZHU Lihuan  WEI Yumiao
Institution:(Ezhou Central Hospital,Ezhou,Hubei,China 436000;Wuhan Union Medical College Hospital,Wuhan,Hubei,China 430022)
Abstract:Objective To investigate the efficacy of tolvaptan in the treatment of chronic pulmonary heart disease with heart failure.Methods A total of 104 patients with chronic pulmonary heart disease with heart failure admitted to the Ezhou Central Hospital were selected and divided into the study group and the control group according to the random number table method,52 cases in each group.The patients in the control group were treated with torasemide,while the patients in the study group were treated with tolvaptan.Both groups were treated for one week.Results The total effective rate of the study group was 98.08%,which was significantly higher than 84.62%of the control group(P<0.05).The incidence of adverse reactions in the study group was 3.85%,which was significantly lower than 17.31%in the control group(P<0.05).After treatment,the urine volume per unit time,blood sodium,plasma colloid osmotic pressure and left ventricular ejection fraction(LVEF)in the two groups were significantly higher than those before treatment,and those in the study group were significantly higher than those in the control group(P<0.05).After treatment,the N-terminal pro-brain natriuretic peptide(NT-proBNP)in the two groups was significantly lower than that before treatment,and that in the study group was significantly lower than that in the control group(P<0.05).After treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)in the two groups were significantly lower than those before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).There was no significant difference in serum potassium between the two groups before and after treatment(P>0.05).Conclusion Tolvaptan is effective in the treatment of chronic pulmonary heart disease with heart failure,it has a good diuretic effect and high safety,but it has a certain impact on blood pressure,so attention should be paid to monitoring blood pressure in clinical use.
Keywords:chronic pulmonary heart disease  heart failure  tolvaptan  torasemide  efficacy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号